Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000049454 | SCV001582267 | pathogenic | Glycine encephalopathy | 2020-12-03 | criteria provided, single submitter | clinical testing | This variant is not present in population databases (ExAC no frequency). This sequence change creates a premature translational stop signal (p.Asp482Glyfs*10) in the GLDC gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in GLDC are known to be pathogenic (PMID: 16601880). This variant has been observed in individual(s) with clinical features of glycine encephalopathy (PMID: 16450403). This variant is also known as c.1443insG in the literature. ClinVar contains an entry for this variant (Variation ID: 56045). For these reasons, this variant has been classified as Pathogenic. |
Juha Muilu Group; Institute for Molecular Medicine Finland |
RCV000049454 | SCV000081888 | probable-pathogenic | Glycine encephalopathy | no assertion criteria provided | not provided | Converted during submission to Likely pathogenic. | |
Natera, |
RCV000049454 | SCV002075773 | pathogenic | Glycine encephalopathy | 2020-06-08 | no assertion criteria provided | clinical testing |